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NEMO is a key component of antiviral signaling. Belgnaoui et al. (2012) discover that linear ubiquitination of
NEMO at a late phase of virus infection switches NEMO from a positive to a negative regulator of RIG-I-medi-
ated interferon (IFN) induction by disrupting the VISA/MAVS-TRAF3 complex and thus terminating the anti-
viral response.The innate immune response acts as the
first line of host defense against viral
infection. Upon infection, viral nucleic
acids, replicative intermediates, and tran-
scription products are recognized by
a subset of pattern recognition receptors
(PRRs). In the case of RNA viruses, viral
RNAs are detected by at least two classes
of PRRs, including the membrane-bound
Toll-like receptors (TLRs) and cytosolic
RIG-I-like receptors (RLRs). Detection of
viral RNAs by these PRRs triggers sig-
naling pathways leading to the activation
of multiple transcription factors such as
IRF3 and NF-kB. These transcription
factors act either alone or in cooperation
to induce expression of numerous down-
stream genes, including type I interferons
(IFNs), proinflammatory cytokines, and
other antiviral genes (ISGs), leading to
antiviral responses (Loo and Gale, 2011).
While TLRs such as TLR3 recognize
incoming viral RNAs in the endosomes
of certain immune cells, the cytosolic
RLRs, including RIG-I and MDA5, detect
replicated viral RNAs in the cytoplasm of
most cell types. Therefore, the cytosolic
RLRs play a more general role in the
innate immune response against RNA
viruses. Upon binding to viral RNAs,
RIG-I and MDA5 are recruited to the mito-
chondrial adaptor protein VISA (also
known as MAVS, IPS-1, and Cardif),
which serves as a signaling platform that
assembles multiple proteins involved in
downstream activation of the transcrip-
tion factors NF-kB and IRF3 (Loo and
Gale, 2011; Xu et al., 2005). VISA/MAVS
interacts with TRAF2/6, members of the
TRAF family of cytosolic adaptor proteins,
through its conserved TRAF-binding
motifs, leading to activation of the IKKcomplex composed of IKKa, IKKb, and
NEMO/IKKg. The activated IKK kinase is
responsible for the phosphorylation and
degradation of IkBa and the subsequent
activation of NF-kB. Concomitantly, VISA/
MAVS is also associated with TRAF3, and
this association is important for triggering
NEMO-dependent activation of two pro
tein kinases TBK1 and IKKε. These
kinases phoshorylate IRF3, causing its
dimerization and activation in the nucleus
(Loo and Gale, 2011).
Ubiquitination has emerged as a central
posttranslational regulatorymechanism in
the positive and negative control of anti-
viral signaling (Bhoj and Chen, 2009).
Two types of linkages of polyubiquitin
chains, K48 and K63 (polyubiquitin chains
linked through lysine at position 48 or 63
of ubiquitin, respectively), have been
extensively investigated so far. In most
cases, K48-linked polyubiquitin chains
target their substrates for proteasome-
dependent degradation, whereas K63-
linked polyubiquitin chains modulate
substrate functions by regulating their
cellular location or protein-protein inter-
actions. Various studies have demon-
strated that RIG-I/MDA5-mediated anti-
viral signaling pathways are extensively
regulated by K48- and K63-linked polyu-
biquitination. For example, K63-linked
polyubiquitination of RIG-I by TRIM25,
an E3 ubiquitin ligase, enhances the
binding of RIG-I to VISA/ MAVS. Several
TRAF proteins, including TRAF2,3,5,6,
and cIAP1/2, are themselves E3 ubiquitin
ligases, which catalyze K63-linked polyu-
biquitination and are required for virus-
triggered induction of type I IFNs. On the
other hand, several components of
the virus-triggered signaling pathways,Cell Host & Microbe 12including VISA/ MAVS, TRAF3,6, and
IRF3, are targeted by distinct E3 ubiquitin
ligases for K48-linked polyubiquitination
and degradation. Interestingly, in vitro
reconstitution experiments demonstrate
that unanchoredK63-polyubiquitin chains
are also capable of activating the RIG-I
pathways (Zeng et al., 2010).
Recently, a new form of polyubiquitin
chains, termed linear ubiquitin chains,
has been identified. These polyubiquitin
chains are linked by a peptide bond
between the amino-terminal methionine
(M1) of one ubiquitin molecule and the
carboxyl-terminal glycine (G76) of the
next. Formation of linear ubiquitin chains
is catalyzed by the linear ubiquitin chain
assembly complex (LUBAC), which con-
sists of three subunits, HOIL-1, HOIP,
and SHARPIN (Emmerich et al., 2011).
Recent studies have established that
linear ubiquitination of NEMO, a key regu-
latory subunit of the IKK complex, plays
important roles in regulation of NF-kB
activation, cell survival, and immune
responses (Emmerich et al., 2011).
Although NEMO is essential in virus-trig-
gered IFN induction pathways, a role of
linear ubiquitination of NEMO in antiviral
response was unknown.
Belgnaoui et al. (2012) demonstrated
that linear ubiquitination turns NEMO
from a positive to a negative regulator of
RIG-I-mediated antiviral signaling by dis-
rupting the VISA/MAVS-TRAF3 complex
at a late phase of viral infection (Figure 1).
Recently, LUBAC-induced linear ubiquiti-
nation of TRIM25was shown to negatively
regulate RIG-I-mediated signaling by dis-
rupting the TRIM25-RIG-I complex (Inn
et al., 2011). However, Belgnaoui et al.
(2012) observed that LUBAC inhibited, August 16, 2012 ª2012 Elsevier Inc. 129
Figure 1. Linear Ubiquitination Terminates Antiviral Response
In the early activation phase of infection, recognition of viral RNA by RIG-I leads to the assembly of a multiprotein complex, which includes involving the VISA/
MAVS adaptor, TRAF proteins, the kinases, and regulators of the NF-kB and IRF3 transcription factors, and results in induction of type I IFNs, ISGs, and proin-
flammatory cytokines. In the late termination phase of infection, LUBAC mediates the linear ubiquitination of NEMO. Linear-ubiquitinated NEMO binds to TRAF3
and disrupts the VISA/MAVS-TRAF3 complex, leading to the inhibition of IRF3-mediated induction of type I IFNs and ISGs but not NF-kB-driven proinflammatory
cytokine IL-6 production. Thus, linear ubiquitination of NEMO at the late phase of infection switches NEMO from a positive to a negative regulator of RIG-I-medi-
ated IFN signaling, effectively putting a brake on the antiviral response. See text for details.
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and upstream of TBK1, a point of control
distinct from the TRIM25-RIG-I check-
point. Knockdown of the LUBAC compo-
nent HOIL-1L in A549 lung epithelial cells
caused an increase in activated IRF3 after
infection, confirming a negative regulatory
role for LUBAC in virus-triggered IRF3
activation pathway (Belgnaoui et al.,
2012). Since NEMO is a known target of
LUBAC and required for virus-triggered
activation of both NF-kB and IRF3, the
authors investigated whether linear ubiq-
uitination of NEMO is responsible for inhi-
bition of IRF3 activation. It turned out that
linear ubiquitination of NEMO increased
its ability to activate NF-kB, yet at the130 Cell Host & Microbe 12, August 16, 2012same time, potently inhibited IRF3 activa-
tion triggered by RIG-I, MDA5 and VISA/
MAVS, but not by TBK1 (Belgnaoui
et al., 2012). These observations suggest
that linear ubiquitination of NEMO differ-
entially regulates the NF-kB and IRF3
activation pathways.
In a more physiologically relevant con-
text, the authors used linear ubiquitina-
tion-deficient SHARPIN-impaired mouse
embryonic fibroblasts (MEFs), termed
cpdm MEFs, for further studies. They
found that endogenous NEMO underwent
linear ubiquitination at a late phase of
virus infection in wild-type but not cpdm
MEFs. Induction of IFN-b and IFNa4 after
viral infection was markedly increased inª2012 Elsevier Inc.cdpm MEFs in comparison to their wild-
type counterparts. In contrast, activation
of NF-kB and induction of NF-kB-driven
IL-6 were markedly decreased in cpdm
MEFs (Belgnaoui et al., 2012). These
results are consistent with the notion
that induction of IFNa4 requires activation
of IRF3, whereas induction of IFN-b
requires cooperative actions of both
NF-kB and IRF3. In contrast, induction
of the proinflammatory cytokine IL-6
requires only the activation of NF-kB.
These results point to a model that linear
ubiquitination of NEMO promotes its
ability to activate NF-kB but converts it
to an inhibitor of virus-induced IRF3 acti-
vation and type I IFN induction (Figure 1).
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MEFs was markedly decreased (Belg-
naoui et al., 2012), probably due to the
increased induction of type I IFNs and
antiviral ISGs in these cells.
Belgnaoui et al. (2012) also addressed
the mechanistic basis for the observed
inhibitory effect of NEMO linear ubiq-
uitination on virus-triggered IRF3 activa-
tion. Because TRAF3 is an essential
positive effecter directly downstream of
VISA/MAVS, the authors assessed the
ability of TRAF3 to interact with linear
ubiquitinated NEMO. They observed a
strong interaction between TRAF3 and
linear ubiquitinated but not unmodified
NEMO. Importantly, at a late phase of
infection, linear ubiquitination of endog-
enous NEMO was coincident with its
binding to TRAF3 in wild-type but not
cpdm MEFs. Furthermore, linear ubiquiti-
nated NEMO was able to compete for
TRAF3 and disrupt the VISA/MAVS-
TRAF3 complex, leading to the termina-
tion of IRF3 activation, suppression of
type I IFNs, and other antiviral ISGs, and
braking of the antiviral response (Belg-
naoui et al., 2012).
Interestingly, an earlier study by Zhao
et al. (2007) identified NEMO as a positive
regulator of RIG-I signaling. The current
study complements these previous find-
ings and reveals a broader role for
NEMO in RIG-I signaling. In the early
phase of infection, NEMO is crucial for
the rapid host response to RNA virus
infection, but at a late phase of infection,NEMO becomes crucial for the proper
termination of IFN signaling, with linear
ubiquitination as the molecular switch
that converts NEMO from a positive to
a negative regulator (Figure 1).
A key question not answered in this
study is how LUBAC is activated and re-
cruited to NEMO following viral infection.
It has been demonstrated that TNF stimu-
lation activates LUBAC (Emmerich et al.,
2011). Whether LUBAC activation fol-
lowing viral infection is indirectly depen-
dent on TNF is unknown. Recently, it has
also been shown that the X-linked inhib-
itor of apoptosis (XIAP) recruits LUBAC
to NOD2, an intracellular pattern recogni-
tion receptor, following bacterial infection
(Damgaard et al., 2012). Since XIAP has
also been identified as a regulator of the
RIG-I-mediated signaling pathway (Na-
khaei et al., 2012), it would be interesting
to investigate whether XIAP plays a role
in the recruitment of LUBAC to the
VISA/MAVS-TRAF3-NEMO signalosome.
Another outstanding question from this
study is whether NEMO in the IKK
complex is linear ubiquitinated at the late
phase of infection. If so, how is this posi-
tive regulator of NF-kB activation eventu-
ally regulated to terminate the induction of
proinflammatory cytokines?
Overall, this study reinforces the
complex multilayered roles of ubiquitina-
tion in the regulation of antiviral response
initiated by the RLRs. This study also
sheds light on the role of linear ubiquitina-
tion in the posttranslational regulation ofCell Host & Microbe 12the innate immune response to invading
pathogens, with linear ubiquitination serv-
ing as a temporal switch to modulate the
functions of NEMO, a key component in
the RLR-mediated signaling pathways.REFERENCES
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